Function's Volume-Driven Pricing Moat

The real moat is not the lab test itself, it is Function turning Quest into a scaled fulfillment engine behind a consumer subscription. At $365 a year, with two testing windows, 160 plus annual lab tests, and members completing more than 50 million lab tests since 2023, Function can push down the unit cost of each draw and panel while keeping the customer relationship, the software layer, and the recurring revenue for itself.1 2 3

• Function is buying commodity lab processing and wrapping it in a higher margin membership. Quest provides the national draw network, more than 2,000 locations, while Function controls signup, scheduling, clinician review, longitudinal tracking, and add on test sales. That setup makes Quest replaceable in theory, but hard to bypass in practice for smaller startups without similar volume.1 3 4
• The volume advantage matters because new competitors are using the same underlying lab infrastructure. Oura Health Panels routes 50 biomarkers through Quest. WHOOP Advanced Labs also uses Quest for in app purchase, scheduling, and results. Function is ahead because it built a dedicated lab membership first, not as an add on to a ring or wearable.4 5 6
• Smaller players can copy the idea, but not the purchasing leverage. Function was at an estimated $100M revenue run rate with about 200,000 subscribers by February 2025, while newer peer Superpower had only $34M in total estimated funding as of October 19, 2025. That gap affects who can commit enough volume to win better lab pricing.1 7

The next step is Function using cheaper test procurement to widen the bundle, not just to protect margin. Lower lab costs support more frequent testing, more specialty panels, and tighter integration with imaging and genomics, which makes the membership harder to cancel and pushes the category toward a few scaled consumer brands sitting on top of the same diagnostic back end.1 2 3 4